Homocysteine levels in women with antiphospholipid syndrome and normal fertile controls

Journal of Reproductive Immunology

Volumn 63, Issue 1, 2004, Pages 23-30

  Lee, Richard M ^a   Brown, Melissa A ^a   Ward, Kenneth ^a   Nelson, Lesa ^a   Branch, D Ware ^a   Silver, Robert M ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

Antiphospholipid syndrome; Homocysteine

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); CYANOCOBALAMIN; FOLIC ACID; HOMOCYSTEINE; PYRIDOXINE;

ADULT; AMINO ACID BLOOD LEVEL; ANTIPHOSPHOLIPID SYNDROME; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FERTILITY; GENE MUTATION; GENOTYPE; HUMAN; HYPERHOMOCYSTEINEMIA; PRIORITY JOURNAL; VITAMIN BLOOD LEVEL;

ADULT; ANTIPHOSPHOLIPID SYNDROME; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FEMALE; FERTILITY; FOLIC ACID; HOMOCYSTEINE; HUMANS; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); POLYMERASE CHAIN REACTION; PREGNANCY; PREGNANCY OUTCOME; VITAMIN B 6;

EID: 3342919094     PISSN: 01650378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jri.2004.01.005     Document Type: Article

References (33)

1. Ames P.R.J., Margaglione M., Tommasino C., Bossone A., Iannaccone L., Brancaccio V. Impact of plasma homocysteine and prothrombin G20120A on primary antiphospholipid syndrome. Blood Coagul. Fibrinolysis. 12:2001;699-704
2. Amengual O., Atsumi T., Khamashta M.A., Hughes G.R.V. The role of the tissue factor pathway in the hypercoagulable state in patients with the antiphospholipid syndrome. Thromb. Haemost. 79:1998;276-281
3. Ames P.R.J., Iannaccone L., Tommasino C., Brillante M., Cimino R., Brancaccio V. Coagulation activation and fibrinolytic imbalance in subjects with idiopathic antiphospholipid antibodies. A crucial role for acquired free protein S deficiency. Thromb. Haemost. 76:1996;190-194
4. Avivi I., Lanir N., Hoffman R., Brenner B. Hyperhomocysteinemia is common in patients with antiphospholpid syndrome and may contribute to expression of major thrombotic events. Blood Coagul. Fibrinolysis. 13:2002;169-172
5. Boushey C.J., Beresford S.A., Omenn G.S., Motulsky A.G. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of increasing folic acid intake. JAMA. 274:1995;1049-1057
6. Branch D.W., Silver P.M., Blackwell J.L., Reading J.C., Scott J.R. Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. Obstet. Gynecol. 80:1992;614-620
7. Camp V.M., Chipponi J., Faraj B.A. Radioenzymatic assay for direct measurement of plasma pyridoxal 5′-phosphate. Clin. Chem. 29:1983;642-644
8. Clarke R., Daly L., Robinson K., Naughten E., Seamus C., Fowler B. Hyperhomocysteinemia: an independent risk factor for vascular disease. N. Engl. J. Med. 324:1991;1149-1155
9. De Stefano V., Martinelli I., Mannucci P.M., et al. The risk of recurrent venous thrombosis among heterozygote carriers of both factor V Leiden and the G202120A prothrombin mutation. N. Engl. J. Med. 341:1999;801-806
10. den Heijer M., Koster T., Blom H.J., Bos G.M.J., Briet E., Reitsma P.H. Hyperhomocysteinemia as a risk factor for deep-vein thrombosis. N. Engl. J. Med. 334:1996;759-762
11. den Heijer M., Rosendaal F.R., Blom H.J., Gerrits W.B.J., Bos O.M.J. Hyperhomocysteinemia and venous thrombosis: a meta-analysis. Thromb. Haemost. 80:1998;874-877
12. Esmon N.L., Safa O., Smirnov M.D., Esmon C.T. Antiphospholipid antibodies and the protein C pathway. J. Autoimmun. 15:2000;221-225
13. Frosst P., Blom H.J., Milos R., Ooyette P., Sheppard C.A., Maffhews R.O., et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat. Genet. 10:1995;111-113
14. Fryer R.H., Wilson B.D., Gubler D.B., Fitzgerald L.A., Rodgers G.M. Homocysteine, a risk factor for premature vascular disease and thrombosis, induces tissue factor activity in endothelial cells. Arterioscler. Thromb. Vasc. Biol. 13:1993;1327-1333
15. Galli M., Finazzi G., Duca F., Norbis F., Moia M. The G1691-A mutation of factor V, but not the G202 10-A mutation of factor II or the C677-T mutation of methylenetetrahydrofolate reductase genes, is associated with venous thrombosis in patients with lupus anticoagulants. Br. J. Haematol. 108:2000;865-870
16. Harris E.N. The second international anti-cardiolipin standardization workshop: the Kingston anti-phospholipid antibody study (KAPS) group. Am. J. Clin. Pathol. 94:1990;476-484
17. Horkico S., Miller E., Dudi E., et al. Antiphospholipid antibodies are directed against apitopes of oxidized phospholipids: recognition of cardiolipin by monoclonal antibodies to epitopes of oxidized low density lipoprotein. J. Clin. Invest. 98:1996;815-825
18. Hughes G.R.V., Harris E.N., Gharavi A.E. The anticardiolipin syndrome. J. Rheumatol. 13:1986;486-489
19. Kojnheer R., Roest M., Haas F.J., De Grout P.G., Derksen R.H. Homocysteine, methylenetetrahydrofolate reductase polymorphism, Antiphospholipid antibodies, and thromboembolic events in systemic lupus erythematosus: a retrospective cohort study. J. Rheumatol. 25:1998;1737-1742
20. Levine J.S., Branch D.W., Rauch J. The antiphospholipid syndrome. N. Engl. J. Med. 346:2002;752-764
21. Loscalzo J. The oxidant stress of hyperhomocysteinemia. J. Clin. Invest. 98:1996;5-7
22. Makris M., Preston F.E., Beauchamp N.J. Co-inheritance of the 20210 allele of the prothrombin gene increases the risk of thrombosis in subjects with familial thrombophilia. Thromb. Haemost. 78:1997;1426-1429
23. Malinow M.R., Kang S.S., Taylor L.M., Wong P.W., Coull B., Inahara T., et al. Prevalence of hyperhomocysteinemia in patients with peripheral arterial occlusive disease. Circulation. 79:1989;1180-1188
24. Midorikawa S., Sanada H., Hashimoto S., Watanabe T. Enhancement by homocysteine of plasminogen activator inhibitor-1 gene expression and secretion from smooth muscle cells. Biochem. Biophys. Res. Commun. 272:2000;182-185
25. Nelen W.L.D.M., Steegers E.A.P., Eskes T.K.A.B., Blom H.J. Genetic risk factor for unexplained recurrent early pregnancy loss. Lancet. 350:1997;261
26. Nelen W.L.D.M., Blom H.J., Steegers E.A.P., den Heijer M., Eskes T.K.A.B. Hyperhomocysteinemia and recurrent early pregnancy loss: a meta-analysis. Fertil. Steril. 74:2000a;1196-1199
27. Nelen W.L.D.M., Butler J., Steegers E.A.P., Blom H.J., Hanselaw A.G.J.M., Eskes T.K.A.B. Maternal homocysteine and chorionic vascularization in recurrent early pregnancy loss. Hum. Reprod. 15:2000b;954-960
28. Petri M., Roubenoff R., Dallal G.E., Nadeau M.R., Selhub J., Rosenberg I.H. Plasma homocysteine as a risk factor for atherothrombotic events in systemic lupus erythematosus. Lancet. 348:1996;1020-1024
29. Ray J.G., Laskin C.A. Folic acid and homocysteine metabolic defects and the risk of placental abruption, preeclampsia and spontaneous pregnancy loss: a systematic review. Placenta. 20(5):1999;19-29
30. Rodgers G.M., Conn M.T. Homocysteine, an atherogenic stimulus, reduces protein C activation by arterial and venous endothelial cells. Blood. 75:1990;895-901
31. Unfried G., Griesmacher A., Weismuller W., Nagele F., Huber J.O., Tempfer C.B. The C677T polymorphism of the methylenetetrahydrofolate reductase gene and idiopathic recurrent miscarriage. Obstet. Gynecol. 99:2002;614-619
32. Welch O.N., Loscaizo J. Homocysteine and atherothrombosis. N. Engl. J. Med. 338:1998;1042-1050
33. Wilson W.A., Gliaravi A.E., Koike T., Lockshin M.D., Branch D.W., Piette J.C., et al. International consensus statement on preliminary classification criteria for antiphospholipid syndrome: report of an international workshop. Arthritis Rheum. 42:1999;1309-1311